 The study evaluated the short and long-term efficacy and safety of exikizumab in patients with psoriasis according to their severity level, using data from uncover, to and uncover, three clinical trials. Both posi less than 20 and posi greater than or equal to 20 groups had significantly more IXEQ2W than ETN treated patients reach posi 75, 90, 100, an absolute posi less than or equal to 5, less than or equal to 2, and less than or equal to 1 at week 12. The study found that exikizumab demonstrated a high level of efficacy and had a consistent safety profile in patients with different baseline psoriasis severity levels. This article was authored by Legios Chemini, Lavisa Bergren, Martin Dawsonbub, and others.